Metastatic breast cancer poses a formidable challenge to global female health and public hygiene. Patients with HER2+ breast cancer typically demonstrate higher mortality rates and rapid recurrences. Despite the notable advantages in high effectiveness and precision for HER2+ cancer therapy. ADCs (Antibody-Drug Conjugates) still face limitations in rapid metabolism and off-target toxi... https://www.ealisboa.com/